巴瑞替尼治疗类风湿关节炎临床试验中乙型肝炎病毒的评估
该研究整合了巴瑞替尼治疗类风湿关节炎的四项III期试验和一项长期扩展研究数据,评估乙型肝炎病毒再激活风险。共2890例患者接受巴瑞替尼治疗,215例基线HBcAb阳性且接受基线后DNA检测的患者中,32例(14.9%)曾出现HBV DNA阳性,8例(3.7%)有单次可定量结果(≥29 IU/mL),其中4例符合再激活定义(HBV DNA≥100 IU/mL),无患者出现临床肝炎证据。结论提示既往HBV暴露的RA患者接受巴瑞替尼治疗期间应监测HBV DNA,必要时可安全使用抗病毒治疗。
要点
- 既往HBV暴露的RA患者接受巴瑞替尼治疗期间应监测HBV DNA。
- 215例HBcAb阳性患者中14.9%曾出现HBV DNA阳性,3.7%有单次可定量结果。
- 8例可定量患者中4例符合再激活定义,无临床肝炎证据。
核心结论
- 既往HBV暴露的RA患者接受包括巴瑞替尼在内的DMARD治疗时可能发生HBV再激活。
- 此类患者治疗期间应监测HBV DNA,必要时可使用抗病毒治疗。
- HBsAg阳性患者接受巴瑞替尼治疗的HBV再激活风险尚不明确。
研究设计与样本
- 整合四项已完成的III期试验和一项正在进行的长期扩展研究(数据截至2017年4月1日)的数据。
- 纳入DMARD初治或对DMARD(包括MTX、其他csDMARD或TNF抑制剂)应答不佳的RA患者。
- 巴瑞替尼治疗患者可能联用csDMARD(包括MTX),或既往接受过MTX或阿达木单抗+MTX等活性对照药治疗。
- 筛查时检测HBsAg、HBcAb和HBsAb,排除HBsAg阳性、HBcAb阳性/HBsAb阴性(日本允许HBV DNA阴性者入组)以及HBsAb阳性且HBV DNA阳性的患者。
- III期研究随机化后,日本对筛查时HBcAb阳性和/或HBsAb阳性患者进行HBV DNA监测,后全球范围对HBcAb阳性患者开展监测。
主要发现
- 共2890例患者接受至少一剂巴瑞替尼治疗(III期暴露6993患者年)。
- 215例基线HBcAb阳性且接受基线后DNA检测的患者中,32例(14.9%)在治疗开始后某一时点HBV DNA阳性。
- 215例中8例(3.7%)有单次可定量结果(≥29 IU/mL)。
- 8例中4例符合HBV再激活定义(HBV DNA≥100 IU/mL),4例永久停用巴瑞替尼,2例暂时中断。
- 无患者出现临床肝炎证据,8例中5例未使用抗病毒治疗。
关键数值与推荐
- HBV再激活定义为HBV DNA水平≥100 IU/mL。
- 单次可定量HBV DNA结果定义为≥29 IU/mL。
- 排除标准包括HBsAg阳性、HBcAb阳性/HBsAb阴性(日本允许HBV DNA阴性者入组)以及HBsAb阳性且HBV DNA阳性。
临床怎么用
- 对既往HBV暴露(HBcAb阳性)的RA患者,接受巴瑞替尼治疗期间应监测HBV DNA。
- 出现HBV DNA可定量或再激活时,可考虑暂停或停用巴瑞替尼,并根据需要启动抗病毒治疗。
- HBsAg阳性患者接受巴瑞替尼治疗的HBV再激活风险未知,需谨慎评估。
局限性
- HBsAg阳性患者被排除,其接受巴瑞替尼治疗的HBV再激活风险未知。
- HBV DNA监测策略在地区和时期上存在差异(日本先于全球,依据 evolving guidance)。
- 部分分析基于基线后接受DNA检测的患者亚组(215例),非全部2890例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reactivation of hepatitis B virus (HBV) replication is a well-recognised complication in patients receiving disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). Limited data exist on HBV reactivation among patients with RA treated with janus kinase (JAK) inhibitors. The objective of the current study was to assess HBV reactivation in clinical trials of baricitinib, an oral selective JAK1 and JAK2 inhibitor in RA. METHODS: Data were integrated from four completed Phase 3 trials and one ongoing long-term extension (data up to 1 April 2017) in patients naïve to DMARDs or who had inadequate response (IR) to DMARDs including methotrexate (MTX)-IR and/or other conventional synthetic DMARD (csDMARD)-IR, or tumour necrosis factor inhibitors-IR. Within the clinical programme, baricitinib-treated patients may have received concomitant csDMARDs including MTX, or previous treatment with active comparators including MTX or adalimumab + MTX. At screening, all patients were tested for HBV surface antigen (HBsAg), core antibody (HBcAb) and surface antibody (HBsAb). Patients were excluded if they had (1) HBsAg+, (2) HBcAb+/HBsAb- (in Japan, could enrol if HBV DNA-) or (3) HBsAb+ and HBV DNA+. HBV DNA monitoring, following randomisation in the originating Phase 3 studies, was performed in Japan for patients with HBcAb+ and/or HBsAb+ at screening, and was later instituted globally for HBcAb+ patients in accordance with evolving guidance for HBV monitoring and management with immunomodulatory therapy. RESULTS: In total, 2890 patients received at least one dose of baricitinib in Phase 3 (6993 patient-years exposure). Of 215 patients with baseline serology suggestive of prior HBV infection (HbcAb+) who received a post-baseline DNA test, 32 (14.9%) were HBV DNA+ at some point following treatment initiation; 8 of 215 patients (3.7%) had a single quantifiable result (≥29 IU/mL). Of these eight patients, four met the definition of reactivation of HBV (HBV DNA level ≥100 IU/mL); baricitinib was permanently discontinued in four patients, and temporarily interrupted in two patients. No patient developed clinical evidence of hepatitis and in five of eight patients, antiviral therapy was not used. CONCLUSION: HBV reactivation can occur among RA patients treated with DMARDs, including baricitinib, with prior HBV exposure. Our data suggest that such patients should be monitored for HBV DNA during treatment and might be treated safely with the use of antiviral therapy as needed. The risk of HBV reactivation in patients with HBsAg treated with baricitinib is unknown.
引用
- Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020. PMID: 32098857. doi:10.1136/rmdopen-2019-001095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。